Azemiglitazone (potassium)

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM[1]. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC) . Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance[2]. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide[3].

Product Specifications

CAS Number

[1314533-27-1]

Product Name Alternative

MSDC-0602K

UNSPSC

12352005

Hazard Statement

H314

Target

Insulin Receptor; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/msdc-0602k.html

Purity

99.53

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C1SC(CC2=CC=C(C=C2)OCC(C3=CC(OC)=CC=C3)=O)C([N+]1)=O.[K-]

Molecular Formula

C19H16KNO5S

Molecular Weight

409.50

Precautions

P260-P264-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P363-P405-P501

References & Citations

[1]Zhouji Chen, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287 (28) :23537-48.|[2]Jerry R Colca, et al. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27 (7) :631-636.|[3]Dakota R Kamm, et al. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem. Jan-Jun 2021;296:100807.